nerve development News
-
Alume Receives SBIR Phase II Grant from the NIH to Support Clinical Trial of ALM-488 to Highlight Nerves in Patients Undergoing Head & Neck Surgery
Alume Biosciences, Inc. (Alume) announced today that it has been awarded a $2.5M Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). This grant will support Alume's clinical development of its novel nerve illumination technology in surgery. The Principal Investigators on this ...
-
Alume Biosciences Granted FDA Fast Track Designation of ALM-488 for Surgical Nerve Visualization
Alume Biosciences, Inc., a clinical stage biotechnology company developing nerve-targeted pharmaceuticals for surgical and therapeutic use, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead compound ALM-488. ALM-488 is an investigational fluorescently labelled nerve targeting pharmaceutical being developed as an adjunct for the ...
-
US FDA Allows Trial to Proceed for Alume Biosciences` Nerve Imaging Candidate
Alume Biosciences, Inc., a biotechnology company developing nerve-targeted pharmaceuticals for surgical and therapeutic use, today announced that it has received a "Study May Proceed" letter from the US Food and Drug Administration (FDA) related to its recently filed Investigational New Drug (IND) application for the use of ALM-488 in head and neck surgery. ALM-488 is an intravenously ...
-
Creative Proteomics Provides HPLC-tMS Analysis Service for Metabolomics Profiling
With years of experience in offering professional and high-quality products for academic use and pharmaceutical industries, Creative Proteomics announces HPLC-tMS analysis service for metabolomics profiling. Metabolomics is an omics method to analyze all metabolites of a certain biological component or cell quantitatively and qualitatively under a specific physiological or pathological condition. ...
-
Creative Proteomics Upgraded Exosome Proteomics Service to Accelerate Biomarker Discovery Research
Creative Proteomics, an integrated CRO company committed to providing a full range of services to support various proteome-related research projects from identification of single proteins to large-scale proteomic studies, has recently upgraded its fully-developed Exosome Proteomics Service to identify and quantify the proteins in exosomes. The company can also help discover biomarkers after ...
-
TISSIUM to present study results at the 76th Annual Meeting of the American Society for Surgery of the Hand
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, has announced its research has been selected for presentation within the scientific program at the 76th Annual Meeting of the American Society for Surgery of the Hand. The event is scheduled to be held virtually and in-person from September 30 – October 2, 2021 in San Francisco, ...
By TISSIUM
-
Lead in Kids’ Blood Linked With Behavioral and Emotional Problems
Emotional and behavioral problems show up even with low exposure to lead, and as blood lead levels increase in children, so do the problems, according to research funded by the National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health. The results were published online June 30 in the journal JAMA Pediatrics. "This research focused on lower blood lead ...
-
Showcase
Aktiv Pharma Group Receives Grant Funding to Develop Tranexamic Acid Autoinjector
Broomfield Colorado 6/25/2022. Aktiv Pharma Group (Aktiv) announced today a grant award from the U.S. Department of Defense (DOD) Defense Health Agency (DHA) Joint Program Committee 6/Combat Casualty Care Research Program (JPC-6/CCCRP) [1] for the continued development of a tranexamic acid (TXA) autoinjector, targeting proposed indications related to prehospital treatment of severe bleeding. ...
-
US farmworkers sue to block use of four toxic pesticides
A coalition of farmworker advocates and environmental groups filed a lawsuit against the U.S. Environmental Protection Agency Friday, seeking to force a halt to the use of four organophosphate pesticides. Some of these pesticides have been detected in California's rural schoolyards and homes, Sequoia National Park, and Monterey Bay. The four organophosphates at issue in the case are methidathion, ...
-
Medovate Industry Partner for Esra Residents & Trainees Workshop Event in Portugal
Medovate is delighted to be sponsoring the European Society for the 4th ESRA Residents & Trainees Workshop event, taking place at the Hospital das Forças Armadas on the 1st and 2nd April in Porto, Portugal. As well as being an Industry Partner, Medovate will also be showcasing the SAFIRA® system (SAFer Injection for Regional Anaesthesia) – a pioneering device which is ...
By Medovate
-
Neuros Medical Announces Completion of Enrollment in the QUEST Pivotal Clinical Study for Chronic Post-Amputation Pain
Neuros Medical, Inc., a medical device company developing innovative high-frequency nerve block technology for patients with intractable post-amputation pain, announced today the completion of enrollment in its pivotal QUEST (High-FreQUEncy Nerve Block for PoST-Amputation Pain) study. QUEST is a 180-subject, randomized, double blinded, active sham controlled clinical trial that is being conducted ...
-
Neuros Medical Raises $38.5M in Series BB Funding for Completion of Pivotal Clinical Study for Chronic Post-Amputation Pain
Neuros Medical, Inc., a medical device company developing innovative high-frequency nerve block technology for patients with intractable post-amputation pain, announced today the close of a Series BB financing totaling $38.5 million. The financing was co-led by new investors Amzak Health and Sectoral Asset Management, joined by InCube Ventures, existing investors U.S. Venture Partners, Osage ...
-
Neuros Medical Announces Key Milestones in the QUEST Pivotal Clinical Study for Chronic Post-Amputation Pain
Neuros Medical, Inc., a medical device company developing innovative high-frequency nerve block technology for patients with intractable post-amputation pain, announced today the achievement of two milestones in its pivotal QUEST (High-FreQUEncy Nerve Block for PoST-Amputation Pain) study. QUEST is a 180-subject, randomized, double blinded, active sham controlled clinical trial that is being ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you